The DOI matches its Crossref record; 33 of the 34 references it cites were found in a registry or an index.
p53 protein accumulation and gene mutations in human glioma cell lines
Abstract
Mutations in, and aberrant expression of, the p53 tumor suppressor gene were assessed in 17 cell lines derived from human malignant brain tumors (glioblastoma multiforme). Ex‐ons 5 through 8 were screened by single strand conformational polymorphism analysis (SSCP), followed by direct DNA sequencing. Mutations were found in 6 of 17 glioma cell lines, i.e., at a frequency similar to that found in primary malignant gliomas. Loss of the wild type allele was observed in 4 of the mutated cell lines. Two cell lines had the same mutation (CGG → TGG; Arg → Trp) in codon 248. Five of 6 mutations were transitions, 4 of which occurred at CpG dinucleotides. In one cell line a 10‐bp deletion at the intron 4/exon 5 junction was found. Five of 6 glioma cell lines contained a mutation identical to that in the respective primary tumor despite prolonged in vitro culture (140‐221 passages). Thus, the acquisition of p53 mutations during culture appears to be infrequent. Two cell lines derived from heterozygous tumors maintained the wild type p53 allele during long term culture. p53 protein levels were assessed by immunofluorescence cytochemistry and immunoprecipitation followed by Western blot analysis and revealed elevated levels of the p53 protein, although to a variable extent, in all cell lines with p53 mutations. A marked p53 protein accumulation was also observed in two cell lines lacking p53 mutations in exons 5 through 8, indicating that a prolonged half life of the gene product is not solely dependent on an aberrant coding sequence. The remaining cell lines had either low levels or no detectable p53 protein; one of the latter contained a gross rearrangement of the p53 gene. Our results suggest that with respect to p53 gene status, glioma cell lines usually resemble the original tumors and may, therefore, be suitable for studying the biological changes associated with p53 mutations in glial tumors.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The absence of detected p53 protein in BT216 can be explained by the fact that deletion mutations resulting in truncated protein do not lead to detectable protein accumulation [23, 24].”
From Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2 -Amplified and TP53 Wild-type Glioblastomas (2016) · cites this paper as [23]
Citations
Cites
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018 · cited 2×
“Three mutations were located at the previously identified hot spots, codons 248 and 273 (Hollstein et al., 1991).”
BackgroundLane, D. P. (1992) · Nature · doi:10.1038/358015a0 · Cited by 5,138 · cited 2×
“It has been proposed (Lane, 1992; Vogelstein and Kinzler, 1992) that the function of p53 is to prevent cells with damaged DNA from dividing until the damage is repaired.”
BackgroundGerm Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other Neoplasms
Malkin, D., Li, F. P., Strong, L. C., Fraumeni, J. F., Nelson, C. E., Kim, D. H., Kassel, J., Gryka, M. A., Bischoff, F. Z., Tainsky, M. A., et al. (1990) · Science · doi:10.1126/science.1978757 · Cited by 3,765 · cited 1×
“Mutations of the p53 tumor suppressor gene have been identified in a wide variety of human neoplasms (Hollstein et al., 1991), including the Li-Fraumeni syndrome hereditary tumors (Malkin et al., 1990).”
BackgroundOrita, M., Suzuki, Y., Sekiya, T., & Hayashi, K. (1989) · Genomics · doi:10.1016/0888-7543(89)90129-8 · Cited by 3,434 · cited 1×
“PCR-SSCP and direct DNA sequencing PCR-SSCP analysis was essentially performed as described by Orita et al. (1989).”
MethodMomand, J., Zambetti, G. P., Olson, D. C., George, D., & Levine, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90644-r · Cited by 3,113 · cited 1×
“The p53 protein can be inactivated by mutation or by forming complexes with oncoproteins of DNA tumor viruses (Linzer and Levine, 1979; Werness ef al., 1990) or with the cellular protein mdm2 (Momand et al., 1992).”
BackgroundMutations in the p53 gene occur in diverse human tumour types
Nigro, J. M., Baker, S. J., Preisinger, A. C., Jessup, J. M., Hosteller, R., Cleary, K., Signer, S. H., Davidson, N., Baylin, S., Devilee, P., et al. (1989) · Nature · doi:10.1038/342705a0 · Cited by 2,733
Association of Human Papillomavirus Types 16 and 18 E6 Proteins with p53
Werness, B. A., Levine, A. J., & Howley, P. M. (1990) · Science · doi:10.1126/science.2157286 · Cited by 2,562
Vogelstein, B. (1992) · Cell · doi:10.1016/0092-8674(92)90421-8 · Cited by 1,862 · cited 4×
“The p53 gene encodes a nuclear 53 kDa phosphoprotein which acts as a transcriptional regulator by forming tetramers which bind to specific DNA sequences and exert a negative regulation of cell proliferation (reviewed by Vogelstein and Kinzler, 1992).”
BackgroundInfluentialLinzer, D. I. H., & Levine, A. J. (1979) · Cell · doi:10.1016/0092-8674(79)90293-9 · Cited by 1,813 · cited 1×
“The p53 protein can be inactivated by mutation or by forming complexes with oncoproteins of DNA tumor viruses (Linzer and Levine, 1979; Werness ef al., 1990) or with the cellular protein mdm2 (Momand et al., 1992).”
BackgroundMolecular basis of base substitution hotspots in Escherichia coli
Coulondre, C., Miller, J. H., Farabaugh, P. J., & Gilbert, W. (1978) · Nature · doi:10.1038/274775a0 · Cited by 1,193 · cited 1×
“The mechanism leading to this base exchange is thought to involve spontaneous hydrolytic deamination of 5-methylcytosine to thymine (Coulondre et aL, 1978), which results in a C -+ T transitiop.”
Background
Cited by
Ishii, N., Maier, D., Merlo, A., Tada, M., Sawamura, Y., Diserens, A., & Van Meir, E. G. (1999) · Brain Pathology · doi:10.1111/j.1750-3639.1999.tb00536.x · Cited by 569
“Alternatively, mutation of TP53gene could occur in culture, but this is an uncommon event (2,39).”
BackgroundMetellus, P., Coulibaly, B., Colin, C., de Paula, A. M., Vasiljevic, A., Taieb, D., Barlier, A., Boisselier, B., Mokhtari, K., Wang, X. W., et al. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0777-8 · Cited by 289
Gomez‐Manzano, C., Fueyo-Margareto, J., Kyritsis, A. P., Steck, P. A., Roth, J. A., McDonnell, T. J., Steck, K. D., Levin, V. A., & Yung, W. K. A. (1996) · PubMed · Cited by 228
The p53 gene and its role in human brain tumors
Bögler, O., Su Huang, H. ‐., Kleihues, P., & Cavenee, W. K. (1995) · Glia · doi:10.1002/glia.440150311 · Cited by 187
Self-citationExpression of the neural RNA‐binding protein Musashi1 in human gliomas
Toda, M., Iizuka, Y., Yu, W., Imai, T., Ikeda, E., Yoshida, K., Kawase, T., Kawakami, Y., Okano, H., & Uyemura, K. (2001) · Glia · doi:10.1002/glia.1034 · Cited by 162
Metadata
- Authors
- Anker, L., Ohgaki, H., Ludeke, B. I., Herrmann, H., Kleihues, P., & Westphal, M.
- Affiliations
- University Medical Center Hamburg-Eppendorf (DE)
- University of Zurich (CH)
- Corresponding author
- Westphal, Manfred
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 1993-12-02
- Volume
- 55
- Issue
- 6
- Pages
- 982-987
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W2002666984
- Cited by
- 66
- References
- 34
- Citations by year
- 2026: 1 · 2019: 1 · 2018: 1 · 2017: 1 · 2015: 1 · 2014: 3 · 2013: 4 · 2012: 1
- FWCI
- 1.22
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- International Journal of Cancer (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- p53, glioma cell lines, glioblastoma, TP53 mutation, p53 accumulation, tumor suppressor, loss of heterozygosity, malignant brain tumors
- MeSH terms
- Base Sequence, Chromosome Deletion, Codon, Exons, Female, Glioma, Humans, Male, Molecular Sequence Data, Precipitin Tests, Tumor Cells, Cultured, Blotting, Western, Polymerase Chain Reaction, Genes, p53, Tumor Suppressor Protein p53, Point Mutation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: p53 protein accumulation and gene mutations in human glioma cell lines. https://app.cochat.ai/papers/10.1002/ijc.2910550618
- The paper
- Anker, L., Ohgaki, H., Ludeke, B. I., Herrmann, H., Kleihues, P., & Westphal, M. (1993). p53 protein accumulation and gene mutations in human glioma cell lines. International Journal of Cancer. https://doi.org/10.1002/ijc.2910550618
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.